More than one-third of the people who had gastric bypass surgery met glycemic control targets three years out, compared with 24 percent who had a different type of bariatric surgery called sleeve gastrectomy. And just 5 percent of people in a group treated with medication alone were able to meet that standard.
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently not FDA approved; it is used in many other countries, such as Japan, India and Europe, as a dual oral agent with metformin or thiazolidinediones.
In prior studies, moderate alcohol consumption has been linked to healthier cardiovascular outcomes. When it comes to moderate alcohol consumption and diabetes the potential health benefits, if any, are not as clear.
New research from the University of Houston Department of Health and Human Performance found impairments in dexterity and sensory function in the hands of type 2 diabetes patients. The study marks the first time such results have been documented in that population.
Today, the biggest risk for tuberculosis is not HIV/AIDS, which led to a surge in cases in the late 1980s, but diabetes. Diabetes impairs the immune system and leaves a person who has been exposed to TB much more likely to develop active disease.
A new study, published in The Lancet Diabetes & Endocrinology, suggests that both the prevention and treatment of these disorders may benefit from addressing poor sleep.
The FDA will delay allowing the type 2 drug empagliflozin to enter the U.S. market until “previously observed deficiencies” at the plant where it is manufactured are fixed. The delay does not call into question the safety or utility of the drug, which is manufactured by Eli Lilly and Boehringer Ingelheim.
A lot of people think that gastric surgeries work by making you eat less. True — but that’s only part of the story.
This post is written by Osama Hamdy, M.D.,Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Management at Joslin Diabetes Center, Assistant Professor of Medicine at Harvard Medical School.
Diabetes is the only harmful side effect linked to statins, the study found, with 3 percent of people on statins being newly diagnosed with diabetes, compared with 2.4 percent of people taking placebos. That means that for every five new cases of diabetes in people taking statins, one is caused by the drug.
A recent New York Times article reports that researchers have found a rare mutation that reduces the risk of developing type 2 diabetes by two thirds, even in obese people.
The investigational type 2 diabetes drug empagliflozin won’t win the FDA’s approval until “previously observed deficiencies” at a manufacturing plant are fixed, the drug’s sponsors said last week.
The pre-filled, single-use pen injector eliminates the need for patients to transfer the medication between a vial and a syringe. It contains the same formulation and dose as the original Bydureon single-dose tray, providing the same continuous release of exenatide.
A recent article in Scientific American discusses a synthetic chemical that has extended the lifespan of lab mice by mimicking the effects of a low-calorie diet.
There has been a fierce debate among dieticians about whether cinnamon can help control blood glucose levels for people with diabetes. While the spice, made from the bark of trees, has long been a part of traditional medicine, clinical trials have offered differing opinions on what it can do to help those with Type 2 […]
Reporting on a study in The Journal of the American Medical Association, Diane Fennell wrote “General measures of obesity, such as body-mass index, total body fat, or [fat under the skin] were not associated with an increased risk of developing Type 2.”
The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer.
A new study based on genetic testing of 150,000 people has found a rare mutation that protects even fat people from getting Type 2 diabetes. The effect is so pronounced — the mutation reduces risk by two-thirds — that it provides a promising new target for developing a drug to mimic the mutation’s effect.
This post is written by Osama Hamdy, M.D., Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Management at Joslin Diabetes Center, Assistant Professor of Medicine at Harvard Medical School.
At 85, Nobel laureate James D. Watson, the co-discoverer of the double-helix structure of DNA, continues to advance intriguing scientific ideas. His latest, a hypothesis on the causation of type 2 diabetes, is to appear 7 pm Thursday US time in the online pages of The Lancet, the prestigious British medical journal.